Literature DB >> 22002807

Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Rui D S Prediger1, Aderbal S Aguiar, Filipe C Matheus, Roger Walz, Layal Antoury, Rita Raisman-Vozari, Richard L Doty.   

Abstract

The causes of Parkinson's disease (PD) are unknown, but there is evidence that exposure to environmental agents, including a number of viruses, toxins, agricultural chemicals, dietary nutrients, and metals, is associated with its development in some cases. The presence of smell loss and the pathological involvement of the olfactory pathways in the early stages of PD are in accord with the tenants of the olfactory vector hypothesis. This hypothesis postulates that some forms of PD may be caused or catalyzed by environmental agents that enter the brain via the olfactory mucosa. In this article, we provide an overview of evidence implicating xenobiotics agents in the etiology of PD and review animal, mostly rodent, studies in which toxicants have been introduced into the nose in an attempt to induce behavioral or neurochemical changes similar to those seen in PD. The available data suggest that this route of exposure results in highly variable outcomes, depending upon the involved xenobiotic, exposure history, and the age and species of the animals tested. Some compounds, such as rotenone, paraquat, and 6-hydroxydopamine, have limited capacity to reach and damage the nigrostriatal dopaminergic system via the intranasal route. Others, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), readily enter the brain via this route in some species and influence the function of the nigrostriatal pathway. Intranasal infusion of MPTP in some rodents elicits a developmental sequence of behavioral and neurochemical changes that closely mimics that seen in PD. For this reason, such an MPTP rodent model appears to be an ecologically valid means for assessing novel palliative treatments for both the motor and non-motor symptoms of PD. More research is needed, however, on this and other ecologically valid models.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22002807     DOI: 10.1007/s12640-011-9281-8

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  213 in total

Review 1.  Epidemiology of neurodegeneration.

Authors:  Richard Mayeux
Journal:  Annu Rev Neurosci       Date:  2003-01-24       Impact factor: 12.449

2.  Recall and recognition memory in Parkinson's disease.

Authors:  E K Breen
Journal:  Cortex       Date:  1993-03       Impact factor: 4.027

3.  Influenza and Parkinson's disease.

Authors:  G Moore
Journal:  Public Health Rep       Date:  1977 Jan-Feb       Impact factor: 2.792

4.  The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein.

Authors:  Amy B Manning-Bog; Alison L McCormack; Jie Li; Vladimir N Uversky; Anthony L Fink; Donato A Di Monte
Journal:  J Biol Chem       Date:  2001-11-13       Impact factor: 5.157

5.  Viral antibodies in the sera from patients with Parkinson disease.

Authors:  R J Marttila; P Arstila; J Nikoskelainen; P E Halonen; U K Rinne
Journal:  Eur Neurol       Date:  1977       Impact factor: 1.710

6.  Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype.

Authors:  Mona Thiruchelvam; Alison McCormack; Eric K Richfield; Raymond B Baggs; A William Tank; Donato A Di Monte; Deborah A Cory-Slechta
Journal:  Eur J Neurosci       Date:  2003-08       Impact factor: 3.386

7.  Neurodegeneration of mouse nigrostriatal dopaminergic system induced by repeated oral administration of rotenone is prevented by 4-phenylbutyrate, a chemical chaperone.

Authors:  Masatoshi Inden; Yoshihisa Kitamura; Hiroki Takeuchi; Takashi Yanagida; Kazuyuki Takata; Yuka Kobayashi; Takashi Taniguchi; Kanji Yoshimoto; Masahiko Kaneko; Yasunobu Okuma; Takahiro Taira; Hiroyoshi Ariga; Shun Shimohama
Journal:  J Neurochem       Date:  2007-06       Impact factor: 5.372

8.  Transport of intranasally instilled fine Fe2O3 particles into the brain: micro-distribution, chemical states, and histopathological observation.

Authors:  Bing Wang; Wei Y Feng; Meng Wang; Jun W Shi; Fang Zhang; Hong Ouyang; Yu L Zhao; Zhi F Chai; Yu Y Huang; Ya N Xie; Hai F Wang; Jing Wang
Journal:  Biol Trace Elem Res       Date:  2007-09       Impact factor: 3.738

9.  Risk is in the air: an intranasal MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) rat model of Parkinson's disease.

Authors:  Rui D S Prediger; Daniel Rial; Rodrigo Medeiros; Cláudia P Figueiredo; Richard L Doty; Reinaldo N Takahashi
Journal:  Ann N Y Acad Sci       Date:  2009-07       Impact factor: 5.691

10.  Maneb potentiates paraquat neurotoxicity by inducing key Bcl-2 family members.

Authors:  Qingyan Fei; Douglas W Ethell
Journal:  J Neurochem       Date:  2008-06-01       Impact factor: 5.372

View more
  21 in total

1.  The Gender-Biased Effects of Intranasal MPTP Administration on Anhedonic- and Depressive-Like Behaviors in C57BL/6 Mice: the Role of Neurotrophic Factors.

Authors:  Marissa Giovanna Schamne; Josiel Mileno Mack; Morgana Moretti; Filipe Carvalho Matheus; Roger Walz; Laurence Lanfumey; Rui Daniel Prediger
Journal:  Neurotox Res       Date:  2018-05-28       Impact factor: 3.911

2.  Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.

Authors:  Juan Segura-Aguilar; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2015-01-29       Impact factor: 3.911

3.  Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD.

Authors:  Silke Nuber; Daniel Tadros; Jerel Fields; Cassia Rose Overk; Benjamin Ettle; Kori Kosberg; Michael Mante; Edward Rockenstein; Margarita Trejo; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-08       Impact factor: 17.088

Review 4.  Olfaction in Parkinson's disease and related disorders.

Authors:  Richard L Doty
Journal:  Neurobiol Dis       Date:  2011-12-20       Impact factor: 5.996

5.  Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Aderbal S Aguiar; Fabrine S M Tristão; Majid Amar; Caroline Chevarin; Laurence Lanfumey; Raymond Mongeau; Olga Corti; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-04-16       Impact factor: 3.911

6.  CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.

Authors:  Fabrine Sales Massafera Tristão; Márcio Lazzarini; Sabine Martin; Majid Amar; Walter Stühmer; Frank Kirchhoff; Lucas Araújo Caldi Gomes; Laurance Lanfumey; Rui D Prediger; Julia E Sepulveda; Elaine A Del-Bel; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2015-09-24       Impact factor: 3.911

Review 7.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

8.  MALDI mass spectrometry imaging of 1-methyl-4-phenylpyridinium (MPP+) in mouse brain.

Authors:  Hanane Kadar; Gael Le Douaron; Majid Amar; Laurent Ferrié; Bruno Figadère; David Touboul; Alain Brunelle; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-12-18       Impact factor: 3.911

9.  Evaluation of nigrostriatal neurodegeneration and neuroinflammation following repeated intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in mice, an experimental model of Parkinson's disease.

Authors:  Fabrine S M Tristão; Majid Amar; Ines Latrous; Elaine A Del-Bel; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-05-21       Impact factor: 3.911

Review 10.  Olfactory dysfunction in Parkinson disease.

Authors:  Richard L Doty
Journal:  Nat Rev Neurol       Date:  2012-05-15       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.